Recovery After Stem-Cell Transplantation for Hematologic Diseases
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PURPOSE: Although the number of autologous and allogeneic stem-cell transplantations (SCT) is increasing, relatively little information about recovery after transplantation is available. Quantitative information appropriate for patient counseling is difficult to discern from the literature. We sought to suggest reasonable expectations for recovery and symptoms after SCT for hematologic malignancies and other disorders using the following measures: (1) objective measures of health status, such as frequency of clinic visits, need for rehospitalization, medication usage, work status, and overall and event-free survival; (2) qualitative assessment of quality of life, such as returning to a normal life, resumption of normal activities, satisfaction with appearance, and whether recovery has occurred; and (3) quantification of specific bothersome symptoms. PATIENTS AND METHODS: Autologous and allogeneic SCT recipients at a tertiary-care transplant center participated in the prospective, longitudinal questionnaire study. RESULTS: Three hundred twenty patients were studied. Questionnaire response rates at 6, 12, and 24 months range from 85% to 88% among survivors. Although autologous patients had better event-free and overall survival, fewer symptoms, and more complete recovery at 6 months, these advantages had largely equalized by 12 months. Specific bothersome symptoms were reported by less than 24% of patients after transplantation, except for fatigue and financial and sexual difficulties, which were more prevalent. CONCLUSION: These findings may help counsel patients considering transplantation and educate them about reasonable expectations for recovery. Overall, the low level of bothersome symptoms and continued recovery through the first year after transplantation are encouraging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McQuellon, R., Russell, G., Cella, D., Craven, B., Brady, M., Bonomi, A., & Hurd, D. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700672 · Cited by 466
Cited by
Pidala, J., Kurland, B., Chai, X., Majhail, N., Weisdorf, D. J., Pavletic, S., Cutler, C., Jacobsohn, D., Palmer, J., Arai, S., et al. (2011) · Blood · doi:10.1182/blood-2010-11-319509 · Cited by 389
Self-citationRecovery and Long-term Function After Hematopoietic Cell Transplantation for Leukemia or Lymphoma
Syrjala, K. L. (2004) · JAMA · doi:10.1001/jama.291.19.2335 · Cited by 349
Quality of life after allogeneic hematopoietic cell transplantation
Pidala, J., Anasetti, C., & Jim, H. (2009) · Blood · doi:10.1182/blood-2008-10-182592 · Cited by 318
Mosher, C. E., Redd, W. H., Rini, C. M., Burkhalter, J. E., & DuHamel, K. N. (2009) · Psycho-Oncology · doi:10.1002/pon.1399 · Cited by 315
“Lastly, a higher percentage of autologous BMT patients were able to enjoy socializing with family and friends compared with allogeneic BMT patients at a 6month follow-up (75 vs 52%), but this difference was not found at 12-month and 24-month follow-ups [31].”
BackgroundInfluentialFraser, C. J., Bhatia, S., Ness, K., Carter, A., Francisco, L., Arora, M., Parker, P., Forman, S., Weisdorf, D., Gurney, J. G., et al. (2006) · Blood · doi:10.1182/blood-2006-02-003954 · Cited by 281
Metadata
- Authors
- Lee, S. J., Fairclough, D., Parsons, S. K., Soiffer, R. J., Fisher, D. C., Schlossman, R. L., Antin, J. H., & Weeks, J. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-01-01
- Volume
- 19
- Issue
- 1
- Pages
- 242-252
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W45351630
- Cited by
- 148
- References
- 1
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.